Condition: Type 2 Diabetes · Sponsor: Hanmi Pharmaceutical Company Limited
A multicenter, randomized, double-blind, phase 3 study to evaluate efficacy and safety of HM11260C in patients with type 2 diabetes mellitus inadequately controlled with metformin and dapagliflozin
This description comes directly from the study's public registry record.
Jee Won Shon · 82-2-410-9037 · jeewon.shon@hanmi.co.kr
Always discuss trial participation with your own doctor first.
| The Catholic University of Korea Bucheon St. Mary's Hospital | Gyeonggi-do, South Korea | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07379333